Company newsCompany release

Johnson & Johnson JNJ

Johnson & Johnson says CAPLYTA improved manic symptoms in second Phase 3 study

Johnson & Johnson said the two positive Phase 3 studies will support a planned U.S. FDA submission of CAPLYTA for bipolar mania.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

On November 10, 2026, Johnson & Johnson announced that Study 452, the second pivotal Phase 3 study of CAPLYTA (lumateperone) for manic episodes with or without mixed features in adults with bipolar I disorder, met its primary endpoint and its secondary endpoint on overall illness severity.

According to the company, CAPLYTA improved manic symptoms and overall illness severity versus placebo at Week 3, with improvement observed as early as Day 3. The results were presented as a late-breaking presentation at the 2026 Neuroscience Education Institute Fall Congress, held November 5-8 in Colorado Springs, Colorado.

The primary endpoint was met, with CAPLYTA producing a 3.7-point greater reduction in Young Mania Rating Scale total score than placebo at Week 3. Nearly twice as many patients achieved a clinical response at Week 3, with 43.9% of patients on CAPLYTA reaching at least a 50% improvement from baseline compared with 23.7% on placebo.

The company said CAPLYTA was well tolerated, with low discontinuation rates and a safety profile consistent with its established profile. The most common treatment-related adverse events reported at a rate of at least 5% and at least twice the placebo rate were dizziness, dry mouth and somnolence/sedation.

Johnson & Johnson said Study 451 and Study 452 together will support the planned U.S. regulatory submission. CAPLYTA is not approved for manic episodes associated with bipolar I disorder, according to the company.

Key facts

Study
Study 452, second pivotal Phase 3 study
Dose
Once-daily CAPLYTA 42 mg versus placebo over three weeks
YMRS change at Week 3
3.7-point greater reduction versus placebo (P<.0001)
Clinical response at Week 3
43.9% on CAPLYTA versus 23.7% on placebo
Presented
2026 Neuroscience Education Institute Fall Congress, November 5-8

All JNJ news

Source: The company's release on PR Newswire, November 10, 2026.

Written by GetSignal with AI from the company's press release. How we make news

Not investment advice.

More company news

Johnson & Johnson first, then the newest

All company news